Fernando Corvillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/678596/publications.pdf

Version: 2024-02-01

1163117 1058476 14 242 8 14 citations h-index g-index papers 16 16 16 342 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Frontiers in Immunology, 2021, 12, 641656.	4.8	14
2	Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer–Simons syndrome). International Journal of Molecular Sciences, 2021, 22, 6608.	4.1	7
3	Immunological features of patients affected by Barraquer-Simons syndrome. Orphanet Journal of Rare Diseases, 2020, 15, 9.	2.7	11
4	The FXII c4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant. Frontiers in Genetics, 2020, 11, 1033.	2.3	9
5	Evidence of ongoing complement activation on adipose tissue from an 11â€yearâ€old girl with Barraquer–Simons syndrome. Journal of Dermatology, 2020, 47, 1439-1444.	1.2	6
6	An overview of lipodystrophy and the role of the complement system. Molecular Immunology, 2019, 112, 223-232.	2.2	21
7	Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Frontiers in Immunology, 2019, 10, 886.	4.8	52
8	Complement as a diagnostic tool in immunopathology. Seminars in Cell and Developmental Biology, 2019, 85, 86-97.	5.0	33
9	Lipodistrofia parcial adquirida y glomerulopatÃa C3: la desregulación del sistema del complemento como mecanismo común. Nefrologia, 2018, 38, 258-266.	0.4	8
10	Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy. Frontiers in Immunology, 2018, 9, 2142.	4.8	23
11	Three cases of C3 glomerulopathy with anti-factor H autoantibodies. Molecular Immunology, 2018, 102, 209.	2.2	О
12	Acquired partial lipodystrophy and C3 glomerulopathy: Dysregulation of the complement system as a common mechanism. Nefrologia, 2018, 38, 258-266.	0.4	6
13	Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clinical and Experimental Immunology, 2016, 184, 118-125.	2.6	24
14	Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. Journal of Clinical Immunology, 2016, 36, 517-527.	3.8	26